Loading
ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.
ZL-1310 is an antibody-drug conjugate developed by Zai Lab (Shanghai). Its target is DLL3 (the sponsor names DLL3). The sponsor states: ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)), in non-small-cell lung cancer. The largest, NCT07218146, plans to enrol 480 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer. Connects to DLL3.
1.ZL-1310's antibody arm binds DLL3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ZL-1310" OR ABSTRACT:"ZL-1310") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZL-1310, not a curated reading list.
Shares DLL3, Non-small-cell lung cancer and the tag pipeline.
Shares DLL3 and the tag pipeline.
Shares DLL3 and the tag pipeline.
Shares DLL3, Non-small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.